Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SENNA+CASSIA · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| SENNA + CASSIA (Naturetti) | EXPERIMENTAL | Daily administration (oral) of one spoon (5g) of Naturetti (SENNA+CASSIA) jelly sugar free at bedtime, during 30 days |
| SENNA+ CASSIA | EXPERIMENTAL | Daily administration (capsule) of Naturetti (SENNA+ CASSIA) at bedtime, during 30 days |
| Placebo | PLACEBO_COMPARATOR | Daily administration (capsule) of placebo at bedtime, during 30 days |
| Name | Type | Description |
|---|---|---|
| SENNA+CASSIA(Naturetti) | DRUG | Daily administration (oral) of one spoon (5g) of Naturetti (SENNA+CASSIA) jelly sugar free at bedtime, during 30 days |
| SENNA+CASSIA | DRUG | Pharmaceutical form: capsule Route of administration: oral Dose regimen: once a day |
| placebo | DRUG | Pharmaceutical form: Capsule Route of administration: oral Dose regimen: once a day |
Inclusion criteria: * Having chronic functional constipation by ROME IIII criteria * Having the majority of the stool as type 1 or 2 by Bristol Stool Scale * Female subjects should be using an effective contraceptive method more than 3 months if they are sexually active and on reproductive stage * ...
SENNA+CASSIA is an investigational small molecule being developed for the treatment of constipation, specifically chronic functional constipation. It is a combination product containing senna and cassia fistula. The drug is currently in Phase 3 clinical development and has completed two trials in Brazil.
SENNA+CASSIA is being developed by Sanofi, a multinational pharmaceutical company listed on the stock exchange under the ticker SNY. The drug is currently in Phase 3 clinical development for the treatment of constipation.
SENNA+CASSIA is in Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Two Phase 3 clinical trials have been completed, both of which were randomized, double-blind, and placebo-controlled.
SENNA+CASSIA has completed two Phase 3 clinical trials. The first, NCT00931853, enrolled 117 participants and evaluated the efficacy and tolerability of the drug in chronic functional constipation. The second, NCT00994851, enrolled 96 participants and also assessed the drug's effect on chronic functional constipation. Both trials were conducted in Brazil.
Yes, SENNA+CASSIA is the same as the combination of Cassia fistula and Senna alexandrina Miller. The clinical trials for this drug specifically evaluated this combination, with trial titles referencing 'Cassia Fistula Plus Senna Alexandrina Miller' as the active treatment.